Recent Updates
Recently added Catalysts
MLYS Positive Sentiment Score: 70/100

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Key Takeaway: Mineralys Therapeutics, Inc. will participate in the Bank of America Securities Health Care Conference from May 14-16, 2024. The management team will host a fireside chat on May 15 at 5:00 PM PDT, discussing their clinical-stage biopharmaceutical efforts. The conference provides a platform for the company to highlight its product candidate, lorundrostat, targeting conditions driven by dysregulated aldosterone, including hypertension and chronic kidney disease. A live webcast will be available for those interested in tuning in.

Market Sentiment Analysis

POSITIVE FACTORS

  • Mineralys Therapeutics is participating in a significant healthcare conference.
  • The company is focused on developing innovative treatments for hypertension and CKD.
  • Management engagement at conferences can attract investor interest and enhance visibility.

Full Press Release Details

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.
Bank of America Securities Health Care Conference:
Date: Wednesday, May 15, 2024
Time: 5:00pm PDT
Format: Fireside Chat
A live webcast of the fireside chat can be accessed by clicking here or under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the fireside chat will be available on the Company’s website for approximately 90 days.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Elixir Health Public Relations
Phone: (1) 515-707-9678

Frequently Asked Questions

What event will Mineralys participate in?

Mineralys Therapeutics will join the Bank of America Securities Health Care Conference.

When will the fireside chat take place?

The fireside chat is scheduled for May 15, 2024, at 5:00 PM PDT.

How can I watch the fireside chat?

The chat will be available as a live webcast on the Mineralys website.

What is Mineralys Therapeutics focused on?

Mineralys develops medicines for hypertension, CKD, and related diseases.

What is lorundrostat?

Lorundrostat is an oral aldosterone synthase inhibitor for cardiorenal conditions.

Last updated: May 6, 2024